Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001
Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011
Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Source: Eur Respir J 2009; 34: 145-155 Year: 2009
Histone deacetylase activity is reduced in COPD. Modulation by theophylline Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Histone deacetylase activity and gene expression in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001
Decreased histone deacetylase activity in COPD Source: Annual Congress 2008 - Epigenetic modifications in lung disease Year: 2008
Single and combined effects of cisplatin, sodium butyrate and sirtinol on covalent histone modifications in human cell lines Source: Eur Respir J 2007; 30: Suppl. 51, 146s Year: 2007
Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: ERS Lung Science Conference 2017 Year: 2017
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
The effects of dexamethasone and IL-1β on histone H3 methylation in A549 cells Source: Eur Respir J 2003; 22: Suppl. 45, 224s Year: 2003
HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice Source: Eur Respir J 2014; 43: 1448-1458 Year: 2014
Histone deacetylases (HDACs) and lung disease Source: Annual Congress 2011 - Why is epigenetics important for lung disease? Year: 2011
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
LSC - 2017 - Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017
Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Radiosensitisation of lung cancer by Z-VAD, a pan-caspase inhibitor: upregulation of autophagy and inhibition of cell proliferation Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009